BiomimX Srl

BiomimX develops organ-on-chip technology, specifically its uBeat platform, which simulates human organ physiology to provide pharmaceutical and cosmetic companies with predictive models for drug efficacy and toxicity testing. The company aims to replace traditional animal testing with human-relevant in vitro models to reduce development timelines and clinical trial failures.